ArticleFrontiers in immunology2018
Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis.PLoS pathogens · 2026Article
- Next-Generation Vaccines Against Neglected Diseases: New Promises from Genetically Modified Live-Attenuated Parasites and RNA Vaccines.Microorganisms · 2026Review
- Leishmaniasis vaccine research: current status and new directions.Parasitology · 2026Review
- Diagnostic potential of GLP recombinant antigens in whole blood assays for Leishmania infantum infection.Parasites & vectors · 2025Article
- Tailoring mRNA lipid nanoparticles for antifungal vaccines.PLoS pathogens · 2025Review
- Design and Expression ofInternational journal of molecular sciences · 2025Article
- Vaccines in Dermatology-Present and Future: A Review.Vaccines · 2025Review
- Decoding trends in mRNA vaccine research: A comprehensive bibliometric study.Human vaccines & immunotherapeutics · 2024Article
- Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate.PLoS pathogens · 2024Article
- mRNA vaccines for infectious diseases - advances, challenges and opportunities.Nature reviews. Drug discovery · 2024Review
- Advances inPathogens (Basel, Switzerland) · 2024Review
- Transmission-Blocking Vaccines against Schistosomiasis Japonica.International journal of molecular sciences · 2024Review
- Immunisation with TransgenicMicroorganisms · 2023Article
- Deletion of MIF gene from live attenuated LdCenScientific reports · 2023Article
- The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.Clinical microbiology reviews · 2023Review
- Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response againstCurrent research in immunology · 2023Article
- Nanotechnology-based mRNA vaccines.Nature reviews. Methods primers · 2023Article
- Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.The Korean journal of parasitology · 2022Article
- Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The rapid generation of strong T cell responses is highly desirable and viral vectors can have potent CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.